4 days Ago By ABMN Staff
Envestnet Asset Management Inc. decreased its stake in Genmab A/S ( NASDAQ:GMAB – Free Report ) by 30.6% during the 4th quarter, HoldingsChannel reports.
The institutional investor owned 723,781 shares of the company’s stock after selling 319,779 shares during the period. Envestnet Asset Management Inc.’s holdings in Genmab A/S were worth $15,105,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in GMAB. Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Genmab A/S in the 4th quarter valued at approximately $392,000. Pitcairn Co.
boosted its position in shares of Genmab A/S by 70.1% during the fourth quarter. Pitcairn Co.
now owns 18,541 shares of the company’s stock worth $387,000 after purchasing an additional 7,640 shares in the last quarter. Trexquant Investment LP boosted its position in shares of Genmab A/S by 495.1% during the fourth quarter.
Trexquant Investment LP now owns 379,936 shares of the company’s stock worth $7,929,000 after purchasing an additional 316,089 shares in the last quarter. OLD Mission Capital LLC acquired a new position in shares of Genmab A/S in the 4th quarter valued at $2,329,000. Finally, StoneX Group Inc.
bought a new stake in shares of Genmab A/S in the 4th quarter valued at $1,380,000. Institutional investors and hedge funds own 7.07% of the company’s stock.
Analysts Set New Price Targets A number of research firms have issued reports on GMAB. William Blair raised Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th.
HC Wainwright restated a “buy” rating and set a $37.00 target price (down from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th.
Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target for the company in a report on Thursday, February 13th. Finally, Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th.
One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $39.
17. Genmab A/S Stock Up 1.0 % Shares of GMAB stock opened at $19.
51 on Wednesday. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $30.
41. The company’s fifty day simple moving average is $20.48 and its 200-day simple moving average is $21.
24. The firm has a market cap of $12.91 billion, a PE ratio of 11.
21, a P/E/G ratio of 2.65 and a beta of 1.07.
Genmab A/S ( NASDAQ:GMAB – Get Free Report ) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.
28 by $0.29. Genmab A/S had a net margin of 36.
30% and a return on equity of 16.78%. On average, equities analysts predict that Genmab A/S will post 1.
45 earnings per share for the current fiscal year. Genmab A/S Company Profile ( Free Report ) Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Read More Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S ( NASDAQ:GMAB – Free Report ). Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.
com's FREE daily email newsletter ..
